<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632031</url>
  </required_header>
  <id_info>
    <org_study_id>17-001</org_study_id>
    <nct_id>NCT03632031</nct_id>
  </id_info>
  <brief_title>Treatment of Wounds Using Oasis® ECM</brief_title>
  <official_title>Treatment of Wounds Using Oasis® Extracellular Matrix in the Community Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Biotech Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Biotech Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to gather post-market clinical evidence on the use of&#xD;
      Oasis ECM as a treatment for different types of chronic wounds in the community setting in&#xD;
      the United Kingdom.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">January 14, 2020</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wound healing</measure>
    <time_frame>12 weeks</time_frame>
    <description>To demonstrate the percentage of patients with wounds progressing to at least 50% healing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound closure- Percentage</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Percentage of patients with complete wound closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound closure- Mean number of weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>mean number of weeks to complete wound closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound closure- Mean Percentage</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Mean percent wound closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life measurement</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>The Wound Quality of Life (QoL) questionnaire is used for measurement of Health-Related Quality of Life in patients with chronic wounds. The total value of this measurement is derived from an average of 17 questions; each question has a value of a minimum of 1 and a maximum of 5. The lower the score, the better the outcome. Subscales are not combined to compute a total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Summary of adverse events reported</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-healing Wound</condition>
  <arm_group>
    <arm_group_label>Patients with chronic non-healing wounds</arm_group_label>
    <description>Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oasis Extracellular Matrix</intervention_name>
    <description>Patients will receive OASIS Extracellular Matrix according to the Instruction for Use</description>
    <arm_group_label>Patients with chronic non-healing wounds</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-healing ulcer (any etiology) present for at least 1 month and treated in&#xD;
        the ambulatory clinic or home healthcare setting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Non-healing ulcer (any etiology) present for at least 1 month and treated in the&#xD;
        ambulatory clinic or home healthcare setting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. Unable or unwilling to provide informed consent&#xD;
&#xD;
          3. Unable or unwilling to comply with the study follow-up schedule, and procedures&#xD;
&#xD;
          4. Simultaneously participating in another investigational drug or device study&#xD;
&#xD;
          5. Target wound area is &lt; 2 cm2 or &gt; 140 cm2 after baseline debridement&#xD;
&#xD;
          6. Target wound has reduced in area by &gt; 40% with 4 weeks of documented standard of care&#xD;
             therapy&#xD;
&#xD;
          7. Known allergy to pig or porcine products&#xD;
&#xD;
          8. Systemic infection&#xD;
&#xD;
          9. Infection of the target wound as determined by the collection of pus&#xD;
&#xD;
         10. Osteomyelitis&#xD;
&#xD;
         11. ABI/TBI &lt; 0.6 obtained within 3 months prior to the screening visit&#xD;
&#xD;
         12. Other exclusions may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leanne Atkin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid Yorkshire Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nursery Park Health Centre</name>
      <address>
        <city>Ashington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinderfields Hospital</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>partial and full-thickness wounds</keyword>
  <keyword>pressure ulcer</keyword>
  <keyword>venous ulcer</keyword>
  <keyword>chronic vascular ulcer</keyword>
  <keyword>diabetic ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

